| 发明名称 |
Antagonists against TNFR1 and methods of use therefor |
| 摘要 |
The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands. |
| 申请公布号 |
US9028822(B2) |
申请公布日期 |
2015.05.12 |
| 申请号 |
US201113181834 |
申请日期 |
2011.07.13 |
| 申请人 |
Domantis Limited |
发明人 |
Brewis Neil D.;Woolven Benjamin P.;Holmes Steve;Tomlinson Ian M.;Lee Jennifer;Enever Carolyn;Basran Amrik;Jones Kate;de Wildt Ruud;Blein Stanislas |
| 分类号 |
A61K39/395;C07K16/24;A61K47/48;C07K16/18;C07K16/28;C07K16/40;A61K39/00 |
主分类号 |
A61K39/395 |
| 代理机构 |
|
代理人 |
Brink Robert H. |
| 主权项 |
1. An antagonist of Tumor Necrosis Factor I (TNFR1) that binds TNFR1 and inhibits signal transduction through TNFR1, (i) wherein said antagonist does not inhibit binding of TNFα to membrane-bound TNFR1, and (ii) wherein said antagonist competes with TAR2h205 (SEQ ID NO: 627 in FIG. 271) for binding to human TNFR1. |
| 地址 |
Brentford, Middlesex GB |
